Abstract
A 48-year-old woman developed interstitial pneumonitis while receiving interferon treatment for chronic hepatitis C. Laboratory studies prior to treatment showed elevated serum alanine aminotransferase levels, but chest X-rays and physical examination revealed no abnormalities suggestive of interstitial pneumonitis. At the 9th week of interferon treatment (total dose, 380MU of recombinant interferon-α, without other medications), the patient began to complain of cough and exertional dyspnea. A chest X-ray film revealed diffuse reticulo-nodular shadows in bilateral lung fields, suggesting a diagnosis of interstitial pneumonitis. A marked increase in lymphocyte count was observed in bronchoalveolar lavage fluid and a diagnosis of interstitial pneumonitis was made as a result of transbronchial lung biopsy. Her clinical symptoms and abnormal lung shadows were reversible, improving within a month of the discontinuation of interferon, and disappearing promptly after exogenous corticosteroid was instituted. This may be the first case of drug-induced interstitial pneumonitis occurring during the course of treatment with interferon alone. We should be aware of the possibility of interstitial pneumonitis developing during treatment of chronic hepatitis C with interferon.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–362.
Hosoda K, Omata M, Yokosuka O, et al. Non-A, Non-B chronic hepatitis is chronic hepatitis C: A sensitive assay for detection of hepatitis C virus RNA in the liver. Hepatology 1992;15:777–781.
Davis GL, Balart LA, Schiffer ER, et al. The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501–1506.
Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321: 1506–1510.
Iino S, Hino K, Kondo, T, et al. Interferon therapy for non-A, non-B chronic hepatitis. Gastroenterol Jpn 1991; 26:224–229.
Conlon KC, Urba WJ, Smith JW, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1900;65:2237–2242.
Schultz M, Muller R, von zur Muhlen A et al. Induction of hyperthyroidism by interferon alpha-2b (letter). Lancet 1989;II: 1452.
Papo T, Marcellin P, Bernau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116:51–53.
Allen D, Cooper JR, White DA, et al. Drug-induced pulmonary disease. Am Rev Respir Dis 1986;133:321–340.
Crystal RG, Bitterman RB, Rennard SI et al. Interstitial lung disease of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med 1984;310:154–166.
Shaw RJ, Benedict SH, Clark RAF, et al. Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF gene activation and up-regulation by interferon gamma. Am Rev Respir Dis 1991;143:167–173.
Baron S, Dianzani F, Stanton GJ, et al. (eds) The interferon system: A current review to 1987. Ausin: University of Texas Press, 1987.
Ueda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992:146:266–268.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moriya, K., Yasuda, K., Koike, K. et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 29, 514–517 (1994). https://doi.org/10.1007/BF02361253
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02361253